VX-770

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

150-250 mg PO BID

Adverse effects

Mechanism of action

  • potentiates function of CTFR

More general terms

References

  1. Accurso FJ et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010 Nov 18; 363:1991. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21083385
    Welsh MJ. Targeting the basic defect in cystic fibrosis. N Engl J Med 2010 Nov 18; 363:2056. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21083391